echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical Research Articles > Acceptance list of important new drugs of CDE on April 1-2

    Acceptance list of important new drugs of CDE on April 1-2

    • Last Update: 2020-04-03
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    The following figure shows the acceptance information of important new drugs on April 1-2 organized by the big smart pharmaceutical group according to the public information of the State Food and drug administration, sorted by registration type for reference Issued by: Ding Yingying / Gu Meiyi reviewed by: Shen Wei * the information in this article is for reference only, and investors shall bear the operational risk accordingly (official wechat interactive DZH News Shanghai station Tel.: + 86-21-2021 9988-31124 Beijing station Tel.: + 86-10-5799 5701 weibo.com/dzhnews) check the attachment to see more stock news, please log in to wisdom 365.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.